Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Champlin

Showing results (51-60 of 217) with videos related to

Pageof 22
Sort By:
Cancer|April 2, 2011
Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcomeIssa F Khouri, Roland Bassett, Nancy Poindexter, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 14, 2009
Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemiaPaul M Armistead, Marcos de Lima, Sherry Pierce, et al.
British Journal of Haematology|June 26, 2003
Tacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantationRaymond Wong, Guillermo Z Beguelin, Marcos de Lima, et al.
Cancer|February 25, 2003
Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemiasMarcos de Lima, Farhad Ravandi, Munir Shahjahan, et al.
Haematologica|February 27, 2025
Maintenance therapy with oral decitabine plus cedazuridine after allogeneic stem cell transplantation for myelodysplastic syndromePortia Smallbone, Terri Lynn Shigle, Oren Paslovsky, et al.
Cancer|July 23, 2003
Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignanciesDimitrios P Kontoyiannis, Ray Hachem, Russell E Lewis, et al.
British Journal of Haematology|July 26, 2002
The anti-apoptotic genes Bcl-X(L) and Bcl-2 are over-expressed and contribute to chemoresistance of non-proliferating leukaemic CD34+ cellsMarina Konopleva, Shourong Zhao, Wei Hu, et al.
Cancer|April 15, 2005
Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experienceHagop Kantarjian, Moshe Talpaz, Susan O'Brien, et al.
Cancer|June 29, 2004
A phase II study of cisplatin, doxorubicin, and ifosfamide with peripheral blood stem cell support in patients with skeletal osteosarcoma and variant bone tumors with a poor prognosisShreyaskumar R Patel, Nicholas Papadopolous, A Kevin Raymond, et al.
The Journal of Infectious Diseases|March 19, 2005
Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent casesDimitrios P Kontoyiannis, Michail S Lionakis, Russell E Lewis, et al.
Pageof 22

Showing results (51-60 of 217) with videos related to

Sort By:
Pageof 22
Cancer|April 2, 2011
Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcomeIssa F Khouri, Roland Bassett, Nancy Poindexter, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 14, 2009
Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemiaPaul M Armistead, Marcos de Lima, Sherry Pierce, et al.
British Journal of Haematology|June 26, 2003
Tacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantationRaymond Wong, Guillermo Z Beguelin, Marcos de Lima, et al.
Cancer|February 25, 2003
Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemiasMarcos de Lima, Farhad Ravandi, Munir Shahjahan, et al.
Haematologica|February 27, 2025
Maintenance therapy with oral decitabine plus cedazuridine after allogeneic stem cell transplantation for myelodysplastic syndromePortia Smallbone, Terri Lynn Shigle, Oren Paslovsky, et al.
Cancer|July 23, 2003
Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignanciesDimitrios P Kontoyiannis, Ray Hachem, Russell E Lewis, et al.
British Journal of Haematology|July 26, 2002
The anti-apoptotic genes Bcl-X(L) and Bcl-2 are over-expressed and contribute to chemoresistance of non-proliferating leukaemic CD34+ cellsMarina Konopleva, Shourong Zhao, Wei Hu, et al.
Cancer|April 15, 2005
Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experienceHagop Kantarjian, Moshe Talpaz, Susan O'Brien, et al.
Cancer|June 29, 2004
A phase II study of cisplatin, doxorubicin, and ifosfamide with peripheral blood stem cell support in patients with skeletal osteosarcoma and variant bone tumors with a poor prognosisShreyaskumar R Patel, Nicholas Papadopolous, A Kevin Raymond, et al.
The Journal of Infectious Diseases|March 19, 2005
Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent casesDimitrios P Kontoyiannis, Michail S Lionakis, Russell E Lewis, et al.
Pageof 22